1. Home
  2. BNC vs TTRX Comparison

BNC vs TTRX Comparison

Compare BNC & TTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo CEA Industries Inc.

BNC

CEA Industries Inc.

HOLD

Current Price

$2.37

Market Cap

287.3M

Sector

Industrials

ML Signal

HOLD

Logo Turn Therapeutics Inc.

TTRX

Turn Therapeutics Inc.

HOLD

Current Price

$10.35

Market Cap

281.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BNC
TTRX
Founded
N/A
2015
Country
United States
United States
Employees
N/A
2
Industry
Industrial Machinery/Components
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
287.3M
281.2M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
BNC
TTRX
Price
$2.37
$10.35
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$8.00
AVG Volume (30 Days)
169.3K
82.5K
Earning Date
07-24-2026
05-31-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.22
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.84
$2.57
52 Week High
$31.62
$11.69

Technical Indicators

Market Signals
Indicator
BNC
TTRX
Relative Strength Index (RSI) 39.09 N/A
Support Level $2.31 N/A
Resistance Level $3.13 N/A
Average True Range (ATR) 0.16 0.00
MACD -0.06 0.00
Stochastic Oscillator 11.54 0.00

Price Performance

Historical Comparison
BNC
TTRX

About BNC CEA Industries Inc.

CEA Industries Inc through its subsidiary is focused on selling environmental control and other technologies and services to the Controlled Environment Agriculture ("CEA") industry. The company provides integrated mechanical, electrical, and plumbing ("MEP") engineering design, proprietary and curated environmental control equipment, and automation offerings that serve the CEA industry. The Company has one operating segment that is dedicated to the manufacture and sale of its products.

About TTRX Turn Therapeutics Inc.

Turn Therapeutics Inc is a clinical-stage biotechnology and medical device development company built around its proprietary platform technology called PermaFusion designed to enhance drug performance. The company is developing non-systemic, non-biologic topical immunomodulators for inflammatory skin disease. Its program, GX-03, is being studied for moderate-to-severe eczema based on preclinical evidence of cytokine inhibition and reduced eczema severity, as well as a favorable real-world tolerability record from prior cleared medical device indications for the same formula. GX-03 is currently being evaluated in an ongoing, randomized, double-blind, vehicle-controlled clinical study designed to assess its potential as a topical treatment for moderate-to-severe eczema.

Share on Social Networks: